32 related articles for article (PubMed ID: 17294729)
1. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma.
Liu F; Wang P; Jiang X; Tan G; Qiao H; Jiang H; Krissansen GW; Sun X
Cancer Sci; 2008 Oct; 99(10):2055-61. PubMed ID: 19016766
[TBL] [Abstract][Full Text] [Related]
2. The potential mechanism of HIF-1α and CD147 in the development of triple-negative breast cancer.
Chen M; Liu Z; Zheng K; Hu C; Peng P
Medicine (Baltimore); 2024 Jun; 103(23):e38434. PubMed ID: 38847725
[TBL] [Abstract][Full Text] [Related]
3. FBP1 expression is associated with basal-like breast carcinoma.
Shi L; Zhao C; Pu H; Zhang Q
Oncol Lett; 2017 May; 13(5):3046-3056. PubMed ID: 28529559
[TBL] [Abstract][Full Text] [Related]
4. Expression of multidrug resistance protein P-glycoprotein in correlation with markers of hypoxia (HIF-1α, EPO, EPO-R) in invasive breast cancer with metastasis to lymph nodes.
Badowska-Kozakiewicz AM; Sobol M; Patera J
Arch Med Sci; 2017 Oct; 13(6):1303-1314. PubMed ID: 29181060
[TBL] [Abstract][Full Text] [Related]
5. HIF-1α and mTOR - Possible Novel Strategies of Targeted Therapies in p16-positive and -negative HNSCC.
Kramer B; Polit M; Birk R; Rotter N; Aderhold C
Cancer Genomics Proteomics; 2018; 15(3):175-184. PubMed ID: 29695399
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the hypoxic tumor environment in hepatocellular carcinoma using RNA interference.
Choi SH; Park JY
Cancer Cell Int; 2017; 17():3. PubMed ID: 28053598
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease.
Bluff JE; Menakuru SR; Cross SS; Higham SE; Balasubramanian SP; Brown NJ; Reed MW; Staton CA
Br J Cancer; 2009 Aug; 101(4):666-72. PubMed ID: 19623180
[TBL] [Abstract][Full Text] [Related]
8. HIF-1α in colorectal carcinoma: review of the literature.
Ioannou M; Paraskeva E; Baxevanidou K; Simos G; Papamichali R; Papacharalambous C; Samara M; Koukoulis G
J BUON; 2015; 20(3):680-9. PubMed ID: 26214618
[TBL] [Abstract][Full Text] [Related]
9. HIF-1α, VEGF and WT-1 are protagonists in bilateral primary angiosarcoma of breast: a case report and review of literature.
Al-Salam S; Balalaa N; Faour I; Akhter S; Alashari M
Int J Clin Exp Pathol; 2012; 5(3):247-53. PubMed ID: 22558480
[TBL] [Abstract][Full Text] [Related]
10. [HIF-1alpha expression and relationship involving tumor cell proliferation and angiogenesis in human breast carcinoma].
Hao LS; Wang G; Qian K; Luo T; Li XJ; Wu XT
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jan; 38(1):60-3. PubMed ID: 17294729
[TBL] [Abstract][Full Text] [Related]
11. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer.
Schoppmann SF; Fenzl A; Schindl M; Bachleitner-Hofmann T; Nagy K; Gnant M; Horvat R; Jakesz R; Birner P
Breast Cancer Res Treat; 2006 Sep; 99(2):135-41. PubMed ID: 16555123
[TBL] [Abstract][Full Text] [Related]
13. Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas.
Okada K; Osaki M; Araki K; Ishiguro K; Ito H; Ohgi S
Anticancer Res; 2005; 25(4):3003-9. PubMed ID: 16080559
[TBL] [Abstract][Full Text] [Related]
14. [Expression of hypoxia-inducible factor-1alpha and vessel endothelial growth factor in esophageal squamous cell carcinoma and clinico-pathological significance thereof].
Yu ZT; Zhao HF; Shang XB
Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(35):2465-9. PubMed ID: 19080625
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
